Molecular drivers underlying bone metastases in human cancer are not well understood, in part due to constraints in bone tissue sampling. Here, RNA sequencing was performed of circulating tumor cells (CTC) isolated from blood samples of women with metastatic estrogen receptor (ER)+ breast cancer, comparing cases with progression in bone versus visceral organs. Among the activated cellular pathways in CTCs from bone-predominant breast cancer is androgen receptor (AR) signaling. AR gene expression is evident, as is its constitutively active splice variant AR-v7. AR expression within CTCs is correlated with the duration of treatment with aromatase inhibitors, suggesting that it contributes to acquired resistance to endocrine therapy. In an established breast cancer xenograft model, a bone-tropic derivative displays increased AR expression, whose genetic or pharmacologic suppression reduces metastases to bone but not to lungs. Together, these observations identify AR signaling in CTCs from women with bonepredominant ER+ breast cancer, and provide a rationale for testing androgen inhibitors in this subset of patients. Implications: This study highlights a role for the AR in breast cancer bone metastasis, and suggests that therapeutic targeting of the AR may benefit patients with metastatic breast cancer. Mol Cancer Res; 16(4); 720-7.

AR expression in breast cancer CTCs associates with bone metastases

Bersani F.;
2018

Abstract

Molecular drivers underlying bone metastases in human cancer are not well understood, in part due to constraints in bone tissue sampling. Here, RNA sequencing was performed of circulating tumor cells (CTC) isolated from blood samples of women with metastatic estrogen receptor (ER)+ breast cancer, comparing cases with progression in bone versus visceral organs. Among the activated cellular pathways in CTCs from bone-predominant breast cancer is androgen receptor (AR) signaling. AR gene expression is evident, as is its constitutively active splice variant AR-v7. AR expression within CTCs is correlated with the duration of treatment with aromatase inhibitors, suggesting that it contributes to acquired resistance to endocrine therapy. In an established breast cancer xenograft model, a bone-tropic derivative displays increased AR expression, whose genetic or pharmacologic suppression reduces metastases to bone but not to lungs. Together, these observations identify AR signaling in CTCs from women with bonepredominant ER+ breast cancer, and provide a rationale for testing androgen inhibitors in this subset of patients. Implications: This study highlights a role for the AR in breast cancer bone metastasis, and suggests that therapeutic targeting of the AR may benefit patients with metastatic breast cancer. Mol Cancer Res; 16(4); 720-7.
16
4
720
727
Abdominal Neoplasms; Alternative Splicing; Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplastic Cells, Circulating; Receptors, Androgen; Sequence Analysis, RNA; Single-Cell Analysis
Aceto N.; Bardia A.; Wittner B.S.; Donaldson M.C.; O'Keefe R.; Engstrom A.; Bersani F.; Zheng Y.; Comaills V.; Niederhoffer K.; Zhu H.; Mackenzie O.; Shioda T.; Sgroi D.; Kapur R.; Ting D.T.; Moy B.; Ramaswamy S.; Toner M.; Haber D.A.; Maheswaran S.
File in questo prodotto:
File Dimensione Formato  
MCR-17-0480R2_Merged_PDF.pdf

Accesso aperto con embargo fino al 30/04/2019

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 2.82 MB
Formato Adobe PDF
2.82 MB Adobe PDF Visualizza/Apri
Mol Cancer Res 2018.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 989.19 kB
Formato Adobe PDF
989.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1794754
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 37
social impact